Fluconazole in neonatal disseminated candidiasis.

Wiest, Dawn; Fowler, Sue; Garner, Sandra S.; Simons, D.

doi:10.1136/adc.66.8.1002

Cited by 13 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nach der gegenwartigen Datenlage weist Fluconazol zur Behandlung der systemischen Candidose bei Neugeborenen und Sauglingen unter den vergleichbaren Antimykotika das gunstigste Profil auf: Neben seiner nachgewiesenen Wirksamkeit bei dieser Indikation bei K n d e r n unter einem Jahr ist die Vertraglichkeit von Fluconazol auch in dieser Altersgruppe gut belegt j10) 21,22,23,24,45,49].…”

Section: Methodikunclassified

Anwendung von Fluconazol bei Kindern <1 Jahr: Übersicht

Schwarze

Penk

Pittrow

1998

Mycoses

View full text Add to dashboard Cite

For this review, 78 publications for use of fluconazole in children below 1 year of age were evaluated with a total of 726 patients. The range of fluconazole dosage was 2-50 mg/kg/day with 162 days as maximum duration of treatment. According to the present experience, fluconazole seems to be an efficacious and well tolerated therapy against systemic candidosis and candidemia in children below 1 year of age, including neonates and very low birth-weight infants (VLBWI). The recommended daily dosage is 6 mg/kg. In patients with impaired renal function, the daily dose should be reduced in accordance with the guidelines given for adults. In neonates during the first two weeks of life, this dosage should be administered only every 72 hours. In weeks two to four of life, the same dose should be given every 48 hours. After that daily dosing is appropriate. This posology is derived from the age-related pharmacokinetics of fluconazole with a higher volume of distribution and a prolonged plasma elimination half life especially during the first month of life. Drug monitoring during treatment should be performed to ensure therapeutic plasma concentrations of fluconazole within a range between 4 and 20 micrograms/ml. The benefit of fluconazole should be investigated in prospective studies for treatment of systemic candidosis with administration of higher dosages as well as for early empiric therapy in VLBWI.

show abstract

Section: Methodikunclassified

Anwendung von Fluconazol bei Kindern <1 Jahr: Übersicht

Schwarze

Penk

Pittrow

1998

Mycoses

View full text Add to dashboard Cite

show abstract

“…The other pharmacokinetic variables did not correlate with postnatal or postconceptional age. Wiest et al (64) report a case of systemic candidiasis in a preterm infant who was treated with fluconazole after treatment with amphotericin B and flucytosine failed. They determined the concentrations of fluconazole in serum and used a first-order, one-compartment model to determine the pharmacokinetic parameters for fluconazole.…”

Section: Fluconazolementioning

confidence: 99%

“…Relapses were due to persistence of the predisposing conditions. In the other articles reviewed here, treatment with fluconazole was successful (7,9,15,60,64). The concentrations of fluconazole in cerebrospinal fluid were determined by Cruciani et al (Table 3) (15).…”

Section: Fluconazolementioning

confidence: 99%